Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

Clinical Cancer Research

Volumn 21, Issue 3, 2015, Pages 652-657

  Candido dos Reis, Francisco J ^a   Song, Honglin ^b   Goode, Ellen L ^c   Cunningham, Julie M ^c   Fridley, Brooke L ^d   Larson, Melissa C ^c   Alsop, Kathryn ^e   Dicks, Ed ^b   Harrington, Patricia ^b   Ramus, Susan J ^f   De Fazio, Anna ^g   Mitchell, Gillian ^e   Fereday, Sian ^e   Bolton, Kelly L ^h   Gourley, Charlie ⁱ   Michie, Caroline ^j   Karlan, Beth ^k   Lester, Jenny ^k   Walsh, Christine ^k   Cass, Ilana ^k   Olsson, Håkan ^l   Gore, Martin ^m   Benitez, Javier J ⁿ   Garcia, Maria J ⁿ   Andrulis, Irene ^o   Mulligan, Anna Marie ^p   Glendon, Gord ^p   Blanco, Ignacio ^q   Lazaro, Conxi ^q   Whittemore, Alice S ^r   McGuire, Valerie ^r   Sieh, Weiva ^r   Montagna, Marco ^s   Alducci, Elisa ^s   Sadetzki, Siegal ^t   Chetrit, Angela ^t   Kwong, Ava ^u   Kjaer, Susanne K ^v   Jensen, Allan ^v   Høgdall, Estrid ^w   Neuhausen, Susan ^x   Nussbaum, Robert ^y   Daly, Mary ^z   Greene, Mark H ^h   Mai, Phuong L ^h   Moysich, Kirsten ^aa   Toland, Amanda E ^ab   Lambrechts, Diether ^ac   Ellis, Steve ^b   Frost, Debra ^b   Brenton, James D ^b,ad,ae   Tischkowitz, Marc ^b   Easton, Douglas F ^b   Antoniou, Antonis ^b   Chenevix Trench, Georgia ^af   Gayther, Simon A ^f   Bowtell, David ^e   Pharoah, Paul D P ^b   more..

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY OF DUNDEE   (United Kingdom)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l LUND UNIVERSITY   (Sweden)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁿ Structural Biology and Biocomputing Programme   (Spain)

^o UNIVERSITY OF TORONTO   (Canada)

^p UNIVERSITY HEALTH NETWORK   (Canada)

^q CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^r STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^t GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^u Cancer Center   (Hong Kong)

^v DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^w UNIVERSITY OF COPENHAGEN   (Denmark)

^x CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^y UNIVERSITY OF CALIFORNIA   (United States)

^z FOX CHASE CANCER CENTER   (United States)

^aa ROSWELL PARK CANCER INSTITUTE   (United States)

^ab OHIO STATE UNIVERSITY   (United States)

^ac UNIVERSITY OF LEUVEN   (Belgium)

^ad CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^ae Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^af QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; GENETIC ASSOCIATION; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; SHORT TERM SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; AGED; CANCER GRADING; CANCER STAGING; GENETICS; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL;

AGED; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84961291899     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2497     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi24-vi32.
3. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011;121:353-7.
4. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16.
5. Soegaard M, Kjaer SK, Cox M, Wozniak E, Hogdall E, Hogdall C, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 2008;14:3761-7.
6. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;30:2654-63.
7. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382-90.
8. McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 2013;105:141-8.
9. Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 2014;4:4026.
10. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, et al. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet 2014;23:4703-9.
11. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
12. Keiding N. Delayed Entry. Encyclopedia of biostatistics: John Wiley & Sons, Ltd; 2005.
13. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377-99.
14. Rubin DB. Inference and missing data. Biometrika 1976;63:581-92.
15. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-5.
16. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
17. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-5.
18. Thomson CA, E Crane T, Wertheim BC, Neuhouser ML, Li W, Snetselaar LG, et al. Diet quality and survival after ovarian cancer: results from the Women's Health Initiative. J Natl Cancer Inst 2014;106. pii: dju314.
19. Schumacher M, Olschewski M, Schmoor C. The impact of heterogeneity on the comparison of survival times. Stat Med 1987;6:773-84.
20. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999;59:3547-51.
21. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
22. Samouelian V, Maugard CM, Jolicoeur M, Bertrand R, Arcand SL, Tonin PN, et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004;54:497-504.
23. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120-3.
24. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764-75.
25. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
26. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009;15:1417-27.
27. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20.
28. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15.
29. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-13.